What next for newly diagnosed glioblastoma?

被引：25

作者：

Domingo-Musibay, Evidio ^{[1
]}

Galanis, Evanthia ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 24期

关键词：

bevacizumab; glioblastoma; newly diagnosed; novo-TTF; radiation therapy; temozolomide; INTEGRATED GENOMIC ANALYSIS; CARMUSTINE BCNU WAFERS; RANDOMIZED PHASE-III; GENE-THERAPY; OPEN-LABEL; ADJUVANT TEMOZOLOMIDE; LOCAL CHEMOTHERAPY; STANDARD TREATMENT; RADIATION-THERAPY; GLIADEL WAFERS;

D O I：

10.2217/fon.15.258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune (TM)) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

引用

页码：3273 / 3283

页数：11

共 53 条

[41] A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study [J].

Schuster, James ;

Lai, Rose K. ;

Recht, Lawrence D. ;

Reardon, David A. ;

Paleologos, Nina A. ;

Groves, Morris D. ;

Mrugala, Maciej M. ;

Jensen, Randy ;

Baehring, Joachim M. ;

Sloan, Andrew ;

Archer, Gary E. ;

Bigner, Darell D. ;

Cruickshank, Scott ;

Green, Jennifer A. ;

Keler, Tibor ;

Davis, Thomas A. ;

Heimberger, Amy B. ;

Sampson, John H. .

NEURO-ONCOLOGY, 2015, 17 (06) :854-861

[42] Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol [J].

Souhami, L ;

Seiferheld, W ;

Brachman, D ;

Podgorsak, EB ;

Werner-Wasik, M ;

Lustig, R ;

Schultz, CJ ;

Sause, W ;

Okunieff, P ;

Buckner, J ;

Zamorano, L ;

Mehta, MP ;

Curran, WJ .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (03) :853-860

[43] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].

Stupp, R ;

Mason, WP ;

van den Bent, MJ ;

Weller, M ;

Fisher, B ;

Taphoorn, MJB ;

Belanger, K ;

Brandes, AA ;

Marosi, C ;

Bogdahn, U ;

Curschmann, J ;

Janzer, RC ;

Ludwin, SK ;

Gorlia, T ;

Allgeier, A ;

Lacombe, D ;

Cairncross, JG ;

Eisenhauer, E ;

Mirimanoff, RO ;

Van Den Weyngaert, D ;

Kaendler, S ;

Krauseneck, P ;

Vinolas, N ;

Villa, S ;

Wurm, RE ;

Maillot, MHB ;

Spagnolli, F ;

Kantor, G ;

Malhaire, JP ;

Renard, L ;

De Witte, O ;

Scandolaro, L ;

Vecht, CJ ;

Maingon, P ;

Lutterbach, J ;

Kobierska, A ;

Bolla, M ;

Souchon, R ;

Mitine, C ;

Tzuk-Shina, T ;

Kuten, A ;

Haferkamp, G ;

de Greve, J ;

Priou, F ;

Menten, J ;

Rutten, I ;

Clavere, P ;

Malmstrom, A ;

Jancar, B ;

Newlands, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :987-996

[44]

Stupp R, 2015, J CLIN ONCOL S15, V33

[45] Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial [J].

Stupp, Roger ;

Hegi, Monika E. ;

Gorlia, Thierry ;

Erridge, Sara C. ;

Perry, James ;

Hong, Yong-Kil ;

Aldape, Kenneth D. ;

Lhermitte, Benoit ;

Pietsch, Torsten ;

Grujicic, Danica ;

Steinbach, Joachim Peter ;

Wick, Wolfgang ;

Tarnawski, Rafal ;

Nam, Do-Hyun ;

Hau, Peter ;

Weyerbrock, Astrid ;

Taphoorn, Martin J. B. ;

Shen, Chiung-Chyi ;

Rao, Nalini ;

Thurzo, Laszlo ;

Herrlinger, Ulrich ;

Gupta, Tejpal ;

Kortmann, Rolf-Dieter ;

Adamska, Krystyna ;

McBain, Catherine ;

Brandes, Alba A. ;

Tonn, Joerg Christian ;

Schnell, Oliver ;

Wiegel, Thomas ;

Kim, Chae-Yong ;

Nabors, Louis Burt ;

Reardon, David A. ;

van den Bent, Martin J. ;

Hicking, Christine ;

Markivskyy, Andriy ;

Picard, Martin ;

Weller, Michael .

LANCET ONCOLOGY, 2014, 15 (10) :1100-1108

[46] Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J].

Stupp, Roger ;

Hegi, Monika E. ;

Mason, Warren P. ;

van den Bent, Martin J. ;

Taphoorn, Martin J. B. ;

Janzer, Robert C. ;

Ludwin, Samuel K. ;

Allgeier, Anouk ;

Fisher, Barbara ;

Belanger, Karl ;

Hau, Peter ;

Brandes, Alba A. ;

Gijtenbeek, Johanna ;

Marosi, Christine ;

Vecht, Charles J. ;

Mokhtari, Karima ;

Wesseling, Pieter ;

Villa, Salvador ;

Eisenhauer, Elizabeth ;

Gorlia, Thierry ;

Weller, Michael ;

Lacombe, Denis ;

Cairncross, J. Gregory ;

Mirimanoff, Rene-Olivier .

LANCET ONCOLOGY, 2009, 10 (05) :459-466

[47] Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1 [J].

Verhaak, Roel G. W. ;

Hoadley, Katherine A. ;

Purdom, Elizabeth ;

Wang, Victoria ;

Qi, Yuan ;

Wilkerson, Matthew D. ;

Miller, C. Ryan ;

Ding, Li ;

Golub, Todd ;

Mesirov, Jill P. ;

Alexe, Gabriele ;

Lawrence, Michael ;

O'Kelly, Michael ;

Tamayo, Pablo ;

Weir, Barbara A. ;

Gabriel, Stacey ;

Winckler, Wendy ;

Gupta, Supriya ;

Jakkula, Lakshmi ;

Feiler, Heidi S. ;

Hodgson, J. Graeme ;

James, C. David ;

Sarkaria, Jann N. ;

Brennan, Cameron ;

Kahn, Ari ;

Spellman, Paul T. ;

Wilson, Richard K. ;

Speed, Terence P. ;

Gray, Joe W. ;

Meyerson, Matthew ;

Getz, Gad ;

Perou, Charles M. ;

Hayes, D. Neil .

CANCER CELL, 2010, 17 (01) :98-110

[48] RANDOMIZED COMPARISONS OF RADIOTHERAPY AND NITROSOUREAS FOR THE TREATMENT OF MALIGNANT GLIOMA AFTER SURGERY [J].

WALKER, MD ;

GREEN, SB ;

BYAR, DP ;

ALEXANDER, E ;

BATZDORF, U ;

BROOKS, WH ;

HUNT, WE ;

MACCARTY, CS ;

MAHALEY, MS ;

MEALEY, J ;

OWENS, G ;

RANSOHOFF, J ;

ROBERTSON, JT ;

SHAPIRO, WR ;

SMITH, KR ;

WILSON, CB ;

STRIKE, TA .

NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (23) :1323-1329

[49] A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma [J].

Westphal, M ;

Hilt, DC ;

Bortey, E ;

Delavault, P ;

Olivares, R ;

Warnke, PC ;

Whittle, IR ;

Jääskeläinen, J ;

Ram, Z .

NEURO-ONCOLOGY, 2003, 5 (02) :79-88

[50] Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial [J].

Westphal, Manfred ;

Yla-Herttuala, Seppo ;

Martin, John ;

Warnke, Peter ;

Menei, Philippe ;

Eckland, David ;

Kinley, Judith ;

Kay, Richard ;

Ram, Zvi .

LANCET ONCOLOGY, 2013, 14 (09) :823-833

← 1 2 3 4 5 6 →